

## **Symposia of the 125<sup>th</sup> Annual Meeting of the Pharmaceutical Society of Japan**

### **S42 Pharmacogenomics-Perspectives in Global Drug Development:New Topics for ICH Discussion**

#### **S42-1 Impact of Pharmacogenomics on Drug Development**

Takao Hayakawa (National Institute of Health Sciences)

#### **S42-2 Usefulness and Problem to be solved in Clinical Trials**

Junichi Azuma (Osaka Univ.)

#### **S42-3 Supporting systems in ethical and leagal and social context**

Tohru Masui (National Institute of Health Sciences)

#### **S42-4 Activities and problems of pharmacogenomics in pharmaceutical firm**

Akira Shinagawa (Biomedical Res. Labs., Sankyo co., ltd.)

#### **S42-5 Conversion into economic value**

Kiichiro Tsutani (Univ. Tokyo)

#### **S42-6 Scientific view of the review for approval & ICH destination**

Kazuhiko Chikazawa (Pharm. Food Safety Bureau, MHLW)